Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents.

4550 Background: Pancreatic metastases from renal cell carcinoma (PmRCC) are uncommon and their prognostic role in the era of targeted terapies (TTs) is not well defined. We evaluated the outcome of a cohort of PmRCC patients (pts) who were treated with either surgery and TTs Methods: PmRCC pts treated between 1993 and 2014 were identified from the databases of 11 European centers. Clinical records were retrospectively reviewed and clinical outcome was analyzed. Kaplan-Meier methods and log-rank test were used to evaluate progression-free survival (PFS) and overall survival (OS). Cox proportional hazard models were used to analyse covariates associated to OS Results: A total of 276 pts were evaluated. PmRCC were synchronous to the primary in 80 pts (29%). Pts treated with pancreatic local treatment (PLoT), including surgery, were 77 (28%) while pts receiving systemic treatment were 256 (93%). Pts with only PmRCC were 42 (15%) whereas lung (47%), lymph nodes (28%) and liver (23%) were the most common metas...